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ABSTRACT: The development of engineered nanomaterials is growing
exponentially, despite concerns over their potential similarities to
environmental nanoparticles that are associated with signiﬁcant
cardiorespiratory morbidity and mortality. The mechanisms through
which inhalation of nanoparticles could trigger acute cardiovascular
events are emerging, but a fundamental unanswered question remains:
Do inhaled nanoparticles translocate from the lung in man and directly
contribute to the pathogenesis of cardiovascular disease? In
complementary clinical and experimental studies, we used gold
nanoparticles to evaluate particle translocation, permitting detection
by high-resolution inductively coupled mass spectrometry and Raman
microscopy. Healthy volunteers were exposed to nanoparticles by acute
inhalation, followed by repeated sampling of blood and urine. Gold was
detected in the blood and urine within 15 min to 24 h after exposure,
and was still present 3 months after exposure. Levels were greater following inhalation of 5 nm (primary diameter) particles
compared to 30 nm particles. Studies in mice demonstrated the accumulation in the blood and liver following pulmonary
exposure to a broader size range of gold nanoparticles (2−200 nm primary diameter), with translocation markedly greater
for particles <10 nm diameter. Gold nanoparticles preferentially accumulated in inﬂammation-rich vascular lesions of fat-
fed apolipoproteinE-deﬁcient mice. Furthermore, following inhalation, gold particles could be detected in surgical
specimens of carotid artery disease from patients at risk of stroke. Translocation of inhaled nanoparticles into the systemic
circulation and accumulation at sites of vascular inﬂammation provides a direct mechanism that can explain the link
between environmental nanoparticles and cardiovascular disease and has major implications for risk management in the
use of engineered nanomaterials.
KEYWORDS: nanoparticle, translocation, gold, air pollution, cardiovascular, atherosclerosis
The manufacture of nanomaterials is growing exponen-tially and with this so is the potential for humanexposure. The fate of engineered nanoparticles and
eﬀect on health following exposure are largely unknown.1,2
Since manufactured nanoparticles of diﬀerent types vary in their
ability to cause inﬂammation and toxicity in animal studies,3 we
may anticipate heterogeneity in their impact on humans at
plausible exposure. Given the prominent cardiovascular eﬀects
of nanosized particulate matter in air pollution, our limited
understanding of the potential cardiovascular eﬀects of
engineered nanoparticles, in particular, is a pressing concern.4
Air pollution is a major public and environmental health
issue contributing to up to 7 million premature deaths
worldwide each year.5,6 The adverse eﬀects of particulate air
pollution on cardiovascular health have been established in a
series of major epidemiological studies,7,8 and even transient
exposure to high levels of air pollution may trigger an acute
cardiovascular event.9 Nanosized particulate matter in air
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pollution, such as that derived from vehicle exhaust, remains a
major public health concern.10,11 We have previously
demonstrated that acute exposure to diesel exhaust causes
vascular dysfunction, thrombosis, and myocardial ischemia in
healthy individuals and in patients with coronary heart
disease.12,13 Chronic exposure to particulate air pollution is
associated with the development and progression of the
vascular disease atherosclerosis in animals and man.14,15
While these observations are important, a major area of
uncertainty remains: How do inhaled particles inﬂuence the
pathogenesis of systemic cardiovascular disease? Are inhaled
nanoparticles able to translocate into the circulation and
directly contribute to cardiovascular disease?
Inhaled nanoparticles are able to deposit deep in the lungs
where they induce oxidative stress and inﬂammation.16,17 It has
been hypothesized that inﬂammatory mediators pass into the
systemic circulation18 and indirectly inﬂuence the cardiovas-
cular system. However, evidence of systemic inﬂammation
following exposure is inconsistent and rather modest. An
alternative hypothesis is that inhaled nanoparticles penetrate
the alveolar epithelium and translocate into the circulation and
directly contribute to cardiovascular disease.19,20 It has been
speculated that these processes may be accelerated by
inﬂammation, through increased permeability of the alveolar
wall or through assisted translocation within macrophages.21−23
Evaluation of nanoparticle translocation following inhalation
exposure is challenging because of the small size of particles, the
low deposited mass, and the requirement for extremely
sensitive and speciﬁc methods of detection. Previous studies
in man have been inconsistent due to leaching of radiolabel
from nanoparticles.24,25 While there is no evidence to date that
translocation occurs in man, animal studies have provided more
compelling evidence that nanoparticles are able to trans-
locate.20,26,27 Oberdorster and Kreyling report translocation
and accumulation of particles in the liver.28,29 Whether this
occurs in man and whether those particles entering the
circulation interact with the cardiovascular system is unknown,
especially in relation to areas of the vasculature that are
susceptible to disease where their biological activity is of
greatest risk.
Figure 1. Gold nanoparticle translocation in man. (A) Representative transmission electron micrograph showing gold particles generated by
the spark generator with a primary particle size of 3.8 nm in loose agglomerates (B) with an aerodynamic count median diameter of 18.7 nm
(geometric standard deviation = 1.5). Abbreviations: AFM = atomic force microscopy; DLS = dynamic light scattering; SMPS = scanning
mobility particle sizer; and TEM = transmission electron microscopy. (C) In man, gold was detectable in the bloodstream in some subjects
within 15 min of the 2 h exposure and was detectable in the majority of subjects at 24 h (12/14 subjects, 86%). (D) Quantiﬁcation of gold
concentrations in blood and urine. Blood concentrations were close to the limit of quantiﬁcation (0.03 ng/g of blood; dotted line) at early
time points. Gray symbols represent values below the limit of quantiﬁcation, but above the limit of detection (0.01 ng/g of blood). Data
expressed as median ± interquartile range.
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Here we use complementary clinical and experimental
studies to address whether inhaled nanoparticles translocate
from the lung into the circulation. Gold nanoparticles are used
as model nanoparticles that are, available in relevant size ranges,
eﬀectively inert for controlled human exposure and to facilitate
detection of low levels in systemic tissues through speciﬁc high-
sensitivity techniques. We hypothesize that inhaled nano-
particles will gain access to the bloodstream and accumulate at
sites of vascular inﬂammation.
RESULTS AND DISCUSSION
Particle Translocation in Man. Fourteen healthy male
volunteers were exposed to gold nanoparticles (median primary
particle size of 3.8 nm, present in loose agglomerates of 18.7
nm (geometric standard deviation: 1.5; Figure 1A,B) by
inhalation (116 ± 12 μg/m3; 5.8 ± 0.3 × 106 particles/cm3)
for 2 h during intermittent exercise (Supplementary Figure S1).
Gold exposure was well tolerated and there were no adverse
eﬀects on lung performance (data not shown).
Blood and urine samples were obtained throughout the ﬁrst
24 h and at 3 months. No volunteer had gold detectable in the
bloodstream prior to exposure, but gold was detectable as early
as 15 min after exposure in some subjects and was present in
the majority (12/14 subjects, 86%) at 24 h (Figure 1C). There
was no evidence of a signiﬁcant time-dependent increase in
gold concentration in the blood within the ﬁrst 6 h of exposure
(Figure 1D). Gold was still detectable in blood and urine at 3
months.
Particle Translocation Is Dependent on Particle Size.
To explore if the particle size aﬀected their ability to
translocate, we exposed healthy volunteers to gold particles
with a primary particle size of either ∼4 nm (4.1 ± 0.6 nm
primary diameter) or 34 nm (34 ± 3 nm primary diameter) (n
= 10 and 9 volunteers, respectively; Figure 2A,B). Particles
agglomerated in the aerosol to a median aerodynamic diameter
of 18 and 52 nm, respectively (Figure 2B). Gold was detectable
in the blood at low levels following inhalation of either size of
particle, although levels of the smaller particle were far greater
(Figure 2C). Gold was detectable in the urine following
Figure 2. Eﬀect of particle size on translocation. (A) Representative transmission electron micrograph showing gold particles (4 nm primary
diameter) generated by the spark generator (i) with and (ii) without particle fusing to obtain large (∼34 nm primary diameter) particulates
from the second clinical exposure study. (B) Characteristics for aerosolized gold particle exposures in clinical studies. (C) Levels of gold
detectable in the bloodstream in subjects exposed to diﬀerent sizes of gold particles. (D) Levels of gold detectable in the urine of subjects
exposed to diﬀerent sizes of gold particles. (E) Levels of gold in the blood of mice exposed to 5 weeks of repeated pulmonary instillation with
diﬀerent sizes of gold nanoparticles. (F) murine liver. (G) murine urine. Data expressed as mean ± SEM, unless otherwise stated.
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exposure to 4 nm particles, but not in the urine of volunteers
exposed to the larger particulate (Figure 2D).
To address tissue accumulation over a wider range of particle
sizes, we repeatedly instilled mice with 2, 5, 10, 30, or 200 nm
gold nanoparticles (primary particle size). Gold was detectable
in the blood following exposure to each size of particulate.
However, the incidence of detectable gold, and the
concentration of gold, in the blood was far greater following
exposure to the smaller particles (Figure 2E). A threshold of
particle accumulation (based on the limit of detection using
HR-ICPMS) was observed for a primary diameter of 10−30
nm. Particle accumulation in the liver also followed a similar
trend (Figure 2F), but gold was only detectable in the urine
following exposure to particles ≤5 nm (Figure 2G).
Accumulation of Translocated Particles at Sites of
Vascular Inﬂammation. Given the close association of
nanoparticles with phagocytic inﬂammatory cells, we wished
to explore whether inhaled nanoparticles accumulate at sites of
vascular inﬂammation. Apolipoprotein E knockout mice
(ApoE−/−) were used as a well-established model of
atherosclerosis and fed a high-fat diet to accelerate the
development of vascular lesions. Intratracheal administration
of gold nanoparticles (diameter 5 nm; BBInternational, U.K.;
Figure 3A) or vehicle was conducted twice weekly for 5 weeks
to deliver a total of 110 μg of gold nanoparticles. Blood and
liver samples were taken 24 h after the last instillation, and the
aortic arch and descending aorta were harvested as areas
exhibiting and free from atherosclerosis, respectively.
Instillation of gold nanoparticles was associated with a mild
pulmonary inﬂammatory response (Figure 3B). At autopsy,
gold nanoparticles were present in the alveoli and largely
contained within macrophages (Figure 4A,B). Gold was
detected in the blood of gold-instilled mice at concentrations
of 9.4 ± 1.2 ng/mL, compared with 0.4 ± 0.2 ng/mL in vehicle-
instilled mice (P < 0.0001; Figure 3C). Gold also accumulated
in the liver (Figure 3C).
The aortic arch from ApoE−/− mice developed complex
atherosclerotic plaques rich in lipids and macrophage-derived
foam cells. Gold concentrations in the aortic arch were 10-fold
higher in gold-treated compared to vehicle-treated mice (60 ±
24 vs 6 ± 1 ng/g of tissue; P = 0.023) and exceeded
concentrations in the descending thoracic aorta (12 ± 6 ng/g
of tissue; Figure 3D). Isolated histological sections of
atherosclerotic plaque from gold-treated animals revealed the
presence of clusters of red-purple granules within foam cells
(Figure 4C) similar in appearance to nanoparticles in
suspension. Particulate clusters were seen on transmission
electron micrographs of atherosclerotic plaque from gold-
treated mice that were distinct from commonly demonstrated
electron-dense membranous structures (Figure 4D and
Supplementary Figure S2). The presence of particulate gold
within atherosclerotic plaques was conﬁrmed on silver-
augmented arterial sections of gold-treated, but not vehicle-
treated, mice using Raman spectroscopy (Figure 5 and
Supplementary Figure S3).
In patients with a recent cerebrovascular accident scheduled
to undergo carotid endarterectomy, we evaluated particle
translocation and accumulation at sites of atherosclerosis
(Figure 6A). Twelve patients were recruited, of which three
were exposed to gold nanoparticles (5 nm) for 4 h under
resting conditions 24 h prior to undergoing surgery. Gold was
measurable at concentrations above the limit of quantiﬁcation
in blood from a single patient and urine from 2 patients
following gold exposure (Supplementary Figure S4). Raman
microscopy identiﬁed the presence of gold in the excised
carotid plaque of those patients exposed to gold nanoparticles,
but not in those without prior exposure (Figure 6B,C).
Here we demonstrate that inhaled nanoparticles translocate
from the lung into the circulation in man, where they
accumulate at sites of vascular inﬂammation. Particle trans-
location was size dependent, with greater translocation and
accumulation of smaller nanoparticles. These observations
suggest a direct role of particle size for inhaled nanoparticles in
the pathogenesis of cardiovascular disease and provide a
mechanism whereby exposure to combustion-derived nano-
Figure 3. Accumulation of gold nanoparticles in tissues of ApoE−/−
mice following pulmonary instillation. (A) Transmission electron
micrograph of gold particles used for instillations in mice, with a
primary particle size of 5 nm and a median agglomerate size of 7.8
nm. (B) Instillation of gold nanoparticles caused mild lung
inﬂammation, measured as total cell count in BALF. Mean ±
SEM, ***P < 0.001, unpaired t-test, n = 6. (C) Gold was detectable
in the blood and liver of gold-treated apolipoprotein-E knockout
(ApoE−/−) mice. (D) Gold particles accumulated in areas of the
vasculature rich in atheroma (aortic arch) compared to those free
of plaque (descending aorta). Mean ± SEM, n = 7−8 (preclinical
study). *P < 0.05, ***P < 0.001, Mann−Whitney test compared to
vehicle-treated animals, †P < 0.05, Mann−Whitney test compared
to aortic arch of gold-treated mice.
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particles and manufactured nanoparticles may promote
atherosclerosis and trigger acute cardiovascular events.
Evaluation of nanoparticle translocation following inhalation
exposure is challenging. Nemmar and colleagues previously
demonstrated the presence of 99m technetium (99mTc) in the
bloodstream of healthy volunteers as early as 1 min after
inhalation of 99mTc-labeled carbon nanoparticles.24 However,
subsequent studies could not replicate this ﬁnding,30,25
suggesting that soluble pertechnate salts, rather than nano-
particle translocation, accounted for the early and rapid
detection of radioactivity in the blood. We used insoluble
gold nanoparticles as they are a similar size to combustion-
derived nanoparticles, have low biological activity, and have
been used safely in man as a radio-contrast agent and for drug
delivery.31 Endogenous levels of gold in biological samples are
negligible,32 permitting reliable identiﬁcation and quantiﬁcation
of translocated gold at nanogram levels using high-resolution
inductively coupled plasma mass spectroscopy (HR-ICPMS)
and Raman microscopy.
Our ﬁndings suggest that translocation of nanoparticles into
the circulation occurs rapidly, consistent with translocation via
a passive transport mechanism, with a slow incremental
accumulation in systemic tissues. There was no evidence of a
time-dependent increase in gold concentration in the blood,
suggesting that while gold nanoparticles translocate into the
circulation, this is balanced by clearance. Indeed, gold was
detected in the urine of almost all subjects within 24 h at a
mean concentration of 35 ± 24 ng/mL. Based on the exposure
characteristics of our ﬁrst study (2 h exposure of ∼116 μg/m3
under light exercise), we calculate the total inhaled dose of
particulate to be ∼690 mg. If ∼80 μg of gold was cleared by the
kidneys over 24 h (average volume of urine collected: 2.4 L
containing 35 ng/mL), and, therefore, if this was the sole route
of clearance, we estimate that at least 0.2% of inhaled gold
nanoparticles translocated from the lung into circulation. This
estimate is consistent with those derived from pulmonary
instillation of particles in animal models,33,34 and those derived
from in vitro−in silico modeling.35 The majority of inhaled
nanoparticles are retained in the alveolar region and are slowly
cleared over time.25 In the present study, gold was still
detectable in blood and urine at 3 months, consistent with
ongoing translocation of gold either through the alveolar
membrane or possibly via the gastrointestinal tract after
clearance by the mucociliary escalator. These ﬁndings are
consistent with those of Kreyling and colleagues36,37 who
demonstrated the persistence of radiolabeled iridium nano-
particles in the lung 6 months after a 1 h inhalation in rats, with
detectable levels in extra-pulmonary organs at this time.
The physicochemical properties of the particle that permit
translocation will have important implications both for
environmental particulates and manufactured nanomaterials.
Particle size is one of the most crucial parameters aﬀecting the
biokinetics and subsequent actions of nanoparticles.38,39 Here
we demonstrate in man that there is less translocation of gold
Figure 4. Visualization of gold nanoparticles in the lung and atherosclerotic plaques of ApoE−/− mice. (A) Gold particles were clearly visible
within lungs of gold-treated animals, largely within alveolar macrophages. (B) Computational coloring to illustrate capillaries (red), alveolar
spaces (blue), and gold particles (yellow). (C) Section of atherosclerotic plaque from a gold-treated mouse showing a distinctive cluster of
red-purple granules within a macrophage-derived foam cell. (D) Transmission electron micrograph of atherosclerotic plaque within the aortic
arch. Insets: examples of particle clusters within the plaques of gold-treated mice; med = vascular media, pla = atherosclerotic plaque, lumen =
blood vessel lumen, fc = foam cell, lc = lipid core.
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particles with a primary diameter of 34 nm in comparison to
that of 4 nm particles (∼55 nm and ∼18 nm aerodynamic
diameter of agglomerates, respectively). Our studies in mice
exploited the availability of gold nanoparticles with narrow size
distributions to deﬁne more tightly whether a size threshold is
present for extra-pulmonary translocation. Signiﬁcant trans-
location into the circulation occurred only at primary particle
sizes below 30 nm, with an inverse association between size and
blood levels below this. Others have shown a size-dependent
association for translocation of nanoparticles into the blood of
healthy rats40 that was balanced with clearance by the
kidneys.41 The current studies suggest that clearance from the
circulation via the kidney may have a smaller size threshold (<6
nm),42,43 supporting the data of Balasubramanian et al.39 Thus,
reliance on estimates of particle concentrations in the blood
alone represents only a “snapshot” of several processes
(alveolar deposition, epithelial and endothelial cell penetration,
particle translocation, clearance via the kidneys, uptake into
other tissues such as the liver, etc.), each with their own
conditions for particle passage or retention. Particle surface
charge41,35 and protein interactions44,45 will also be important
to translocation and clearance processes. Similarly, the ability of
the inhaled particulate to induce pulmonary inﬂammation could
alter translocation rates via increases in alveolar permeability46
or raised numbers of alveolar leucocytes that theoretically
represent nonpassive carriers to assist translocation. These
pathways are the subject of ongoing investigations.
The fate of inhaled nanoparticles that translocate into the
circulation remains to be fully established. Recently, uptake of 7
or 20 nm nanoparticles in the aorta following prolonged
inhalation (15 days) was reported in healthy rats.39 The
potential for engineered nanoparticles (ultrasmall super-
paramagnetic particles of iron oxide, ∼30 nm particles) to
accumulate at sites of inﬂammation, including atherosclerotic
plaques, has been considered, but only following intravenous
injection.47 In the present study, we administered nanoparticles
via the lung of a well-validated mouse model of atherosclerosis.
Gold was detected in high concentrations in the liver,
conﬁrming the liver as a primary route of clearance following
translocation. Importantly, nanoparticles also accumulated at
sites of vascular inﬂammation, but not in nonatherosclerotic
blood vessels. The translocation and accumulation of gold
nanoparticles in atherosclerotic plaque were conﬁrmed in man.
While the small sample size did not permit comparison of the
extent of translocation between patients and healthy controls,
Raman microscopy was suﬃciently sensitive to detect
particulate gold in carotid plaque. The cellular and kinetic
mechanisms, as well as the particle characteristics, that
determine the way circulating nanoparticles accumulate with
atherosclerotic plaques require further investigation, although
rheological conditions and inﬂammatory cells are likely to play
a signiﬁcant role in particle accumulation at sites of disease.
If inhaled nanoparticles are to alter the pathogenesis of
atherosclerosis directly, then particles need to access susceptible
sites and have the necessary physiochemical properties to
induce toxicity. Our current studies required the use of an inert
and identiﬁable nanoparticle, thus we could not address the
pathobiological consequences of translocated nanoparticles
Figure 5. Raman spectroscopy to conﬁrm the presence of particulate gold in lung and atherosclerotic plaques of ApoE−/− mice. (A)
Suspensions of gold nanoparticles following conjugation with silver produced a unique Raman spectra (red) that was not seen with either gold
(blue) or silver alone (green). (B) Representative Raman spectra from silver-augmented gold in sections of lung (red) and atherosclerotic
plaques (orange) from a gold-treated mouse, not seen in lung (blue) or plaque (green) sections from a vehicle-treated mouse. Raman spectra
from (C) lung and (D) atherosclerotic plaques. Data expressed as median ± interquartile range. ***P < 0.001, Mann−Whitney test
comparing gold-treated (n = 64 grids from 3 mice) to vehicle-treated (n = 39 grids from 2 mice) mice.
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taken up into atherosclerotic plaques. Indeed, repeated
instillation of gold nanoparticles did not increase the size of
atherosclerotic plaques in the carotid of ApoE−/− mice.
However, combustion-derived nanoparticles are known to
induce oxidative stress and promote inﬂammation, and as
such, are likely to directly promote atherosclerosis should they
translocate and deposit in the vessel wall.17 We cannot address
whether the pro-atherosclerotic eﬀects of exposure to air
pollution are due to accumulation of combustion-derived
nanoparticles at sites of vascular inﬂammation in the present
study, but our observations suggest this is both plausible and
likely if nanoparticles were to accumulate in suﬃcient numbers.
Furthermore, if nanoparticles accumulate in areas of inﬂam-
mation elsewhere in the body, this could have important
implications for other diseases,48 the potential for particles to
cross the placental barrier during pregnancy,49,50 as well as the
progression of, and theranostics for, cancer.51
These ﬁndings have immediate relevance for the nano-
technology industry where a diverse range of engineered
nanomaterials is being developed for an ever-increasing number
of applications. The fate of engineered nanoparticles and eﬀect
on health following exposure are largely unknown,1,2 especially
in relation to the cardiovascular system.4 These studies use gold
nanoparticles, a commonly used nanoparticle, and one that is
being developed for clinical therapeutics. However, the
biokinetics we observe here for gold may also extend to
Figure 6. Gold nanoparticle exposures in patients undergoing carotid endarterectomy. (A) Isolation of atherosclerotic plaque from the carotid
artery. (B) Overlaid representative Raman spectroscopy spectra: black = silver-stained spark-generated gold nanoparticles on glass slide (no
tissue); blue = silver-stained endarterectomy sample from nonexposed patient; and red = silver-stained endarterectomy sample from gold-
exposed patient. (C) Visualization of gold in endarterectomy samples using heat-map of Raman intensity. Highlighted box within tissue
denotes scanned area, with blue-green color representing baseline intensity (no gold) and red color showing high Raman intensity (gold
particulate).
ACS Nano Article
DOI: 10.1021/acsnano.6b08551
ACS Nano XXXX, XXX, XXX−XXX
G
other nanomaterials including those with greater surface
reactivity. Diﬀerent classes of nanomaterials vary greatly in
their ability to cause inﬂammation and cytotoxicity, thus it
follows that there will be marked diﬀerences in their impact on
health in both occupational settings and in the wider
community exposed to nanomaterials. While data are still
relatively sparse, a number of studies suggest that pulmonary
exposure to a range of diﬀerent inhaled nanoparticles may
promote cardiovascular disease.4,52,53 A better understanding of
how nanomaterials cross physiological barriers, and their fate
thereafter, will be vital to allow for a safe-by-design approach
for new nanomaterials.
CONCLUSIONS
We demonstrate that nanoparticles translocate from the lung to
the circulation and selectively accumulate at sites of vascular
inﬂammation in both animal models of disease and in man.
These observations suggest that the fate of inhaled nano-
particles, as well as their size, is crucial for their potential to
aﬀect cardiovascular disease adversely. A greater understanding
of how nanoparticles translocate and accumulate at sites of
disease is of paramount importance for the risk assessment of
both environmental and engineered nanoparticles.
METHODS
Full methods and any associated references are available in the
Supporting Information.
Clinical Studies. All subjects gave their written informed consent,
and the studies were reviewed and approved by the local research
ethics committee according with the Declaration of Helsinki.
Healthy male nonsmoking volunteers aged 18−35 (Supplementary
Tables S1 and S2) were exposed to gold nanoparticles for 2 h via
inhalation, during intermittent exercise, in a specially built human-
controlled exposure chamber (Supplementary Figure S1A,B). Gold
nanoparticles (∼5 nm primary diameter) were freshly generated from
gold electrodes using a commercial spark generator (Palas CFG1000,
Palas GmbH, Karlsruhe, Germany). In subsequent experiments, larger
single spherical particles were generated by extending the residence
time in argon via a growth loop to agglomerate particles, followed by
thermal fusing of particles. Following exposure, volunteers were taken
to the adjacent clinical research facility where blood samples were
obtained before and after gold exposure and at predeﬁned intervals. A
24 h urine sample was also taken, beginning immediately prior to
exposure, from an empty bladder.
Patients presenting to the Lothian Stroke services with a recent
acute cerebrovascular syndrome (transient ischemic attack, amaurosis
fugax, or stroke) and scheduled for carotid endarterectomy were also
recruited (Supplementary Table S3). Patients were exposed to gold
nanoparticles for two periods of 2 h the day prior to their surgery, but
were not requested to exercise. At surgery, the plaque was excised
intact as part of a standard carotid endarterectomy and patch
angioplasty. The specimen was then snap frozen in liquid nitrogen and
transferred to a freezer for subsequent batch analysis.
Animal Studies. All experiments were performed according to the
Animals (Scientiﬁc Procedures) Act 1986 (U.K. Home Oﬃce).
Male apolipoprotein E knockout (ApoE−/−) mice were fed a high-
fat (21% fat) “Western diet” for 8 weeks.15 Gold nanoparticles in
suspension (citrate-coated, primary particle size 5 nm; BBInterna-
tional, U.K.; 50 μL of 2.3 mg/mL), or vehicle, were administered to
the lungs of mice by instillation twice weekly for the last 5 weeks of
feeding (Supplementary Figure S1C). In experiments exploring
particle size, 2, 5, 10, 30, or 200 nm particles (BBInternational)
were used as above, with the exception that stock solutions were
diluted in order that all sizes were of an equivalent mass concentration
(0.8 mg/mL).
Animals were euthanized ∼18 h after the last instillation. Blood
samples from the vena cava and liver biopsies were taken and stored in
soda lime digestion tubes at −80 °C. The lungs were cannulated via a
small incision in the trachea and lavaged 3 times with 0.8 mL of sterile
saline to collect bronchoalveolar lavage ﬂuid for measurement of lung
inﬂammation. The aortic arch area and descending thoracic aorta were
cleaned of perivascular fat, rinsed in saline, blotted dry, and frozen at
−80 °C in digestion tubes. The aortic arch region is used as an area of
vasculature with extensive atherosclerotic lesions of a mixed “complex”
plaque phenotype, whereas the descending aorta is largely free of
atherosclerotic plaques in mice at this end under this feeding regime.15
Quantiﬁcation of Gold in Biological Samples using HR-
ICPMS. Biological samples were completely dissolved in aqua regia
(HNO3 and HCl; 120 °C) and diluted with ultrapure water to a ﬁnal
volume of 10 mL before analysis for gold content using HR-ICPMS
(Element XR, Thermo Fisher, Bremen, Germany).54,55 For quality
control aspects on the relevant ultratrace level, two reference samples
“SEROnorm Trace levels in blood” (supplied by C. N. Schmidt,
Amsterdam, The Netherlands; Supplementary Table S4) were
analyzed, using two diﬀerent batch numbers. The methodological
limit of quantiﬁcation was 0.03 ng/g of blood, and the coeﬃcient of
variation was 5.5% for blood samples run in triplicate.
Detection and Visualization of Gold Nanoparticles in
Biological Tissues. Samples of the aortic arch for transmission
electron microscopy were ﬁxed for 2 h in 3% glutaraldehyde and
postﬁxed for 45 min in 1% osmium tetroxide. Ultrathin sections (60
nm thick) were cut from selected areas, stained in uranyl acetate and
lead citrate, then viewed in a Phillips CM120 transmission electron
microscope.
Biological samples were ﬁxed in 10% neutral-buﬀered formalin
before histological processing and stained with hematoxylin and eosin
(lung) or United States Trichrome (arteries). Atherosclerotic burden
was comprehensively assessed, as previously described.15 The carotid
artery bifurcation was used to quantify atherosclerotic burden in gold-
treated animals, as brachiocephalic arteries were used for detection of
gold by HR-ICMPS.
Raman spectroscopy was performed using unstained histological
sections that had been deparaﬃnized in graded alcohol. Detection of
gold particulate was assisted by conjugation to silver using a LI-silver
enhancement kit (Molecular Probes, Invitrogen, Paisley, U.K.). Tissue
sections were incubated in 50 nM of glycine in phosphate-buﬀered
saline (pH 7.4; 5 min) to block aldehyde groups in the ﬁxation
reagent, then thoroughly rinsed with dH2O to remove all traces of
phosphate ions from PBS. Silver staining reagents were added for 5
min before washing with water and leaving to air dry.
Detection of gold within tissue samples was performed by Raman
spectroscopy (Renishaw inVia, Renishaw U.K.). Raman spectra from
the lung tissue sections were collected with exposure time of 60 s and
10% laser power, at 514 nm. Spectra were quantiﬁed by transforming
data to area under the curve (spectra) between a Raman shift of 950−
1750 cm−1.
Data Analysis. For parametric data (Gaussian distribution) values
reported are mean ± SEM with diﬀerences between groups analyzed
by analysis of variance (ANOVA) with Bonferroni posthoc tests and
Student’s t-tests, where appropriate (GraphPad Prism v6.0a). For
nonparametric (non-normally distributed) data, values are reported as
median ± interquartile range, with diﬀerences between groups
analyzed by Kruskal−Wallis followed by Dunn’s posthoc tests and
Mann−Whitney tests. ROUT’s outlier56 (Q = 1%, GraphPad Prism
v6.0a) was used to detect the presence of outliers in conditions where
normalization to very small tissue weights (aortic arch and descending
aorta) skewed data sets. P < 0.05 was taken as statistically signiﬁcant.
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